Trovagene’s Onvansertib-decitabine combination trial shows promising results
Trovagene, a California-based cancer research company, has announced the successful completion of the second dosing cohort in its Phase 1b/2 trial investigating the Onvansertib-decitabine combination for treating acute myeloid leukaemia (AML). This trial aims to assess the efficacy and safety of Onvansertib, a selective oral Polo-like Kinase 1 (PLK1) inhibitor, when used in conjunction with […]